Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00939159
What this trial is testing

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
M.D. Anderson Cancer Center 17
Not applicableStudy completedNCT02757989
What this trial is testing

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Who this might be right for
MDS
Groupe Francophone des Myelodysplasies 79
Testing effectiveness (Phase 2)Study completedNCT01736683
What this trial is testing

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
AnemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
Merck Sharp & Dohme LLC 74
Testing effectiveness (Phase 2)WithdrawnNCT00446602
What this trial is testing

Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Testing effectiveness (Phase 2)Ended earlyNCT01513317
What this trial is testing

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Janssen Research & Development, LLC 76
Testing effectiveness (Phase 2)Study completedNCT00303472
What this trial is testing

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
ThrombocytopeniaMDSMyelodysplastic Syndromes+1 more
Amgen 72
Large-scale testing (Phase 3)Study completedNCT01381809
What this trial is testing

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Janssen-Cilag International NV 130
Testing effectiveness (Phase 2)Study completedNCT01904682
What this trial is testing

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Who this might be right for
Myelodysplastic Syndromes
Traws Pharma, Inc. 45
Testing effectiveness (Phase 2)Study completedNCT01891968
What this trial is testing

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT00418665
What this trial is testing

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Who this might be right for
Myelodysplastic SyndromesThrombocytopenia
Amgen 39